Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) – HC Wainwright increased their FY2024 earnings estimates for shares of Armata Pharmaceuticals in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.95) for the year, up from their previous estimate of ($1.02). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2024 earnings at ($0.35) EPS and FY2025 earnings at ($1.70) EPS.
Armata Pharmaceuticals Stock Down 11.2 %
NYSEAMERICAN:ARMP opened at $1.99 on Monday. The stock has a market cap of $72.00 million, a P/E ratio of -1.23 and a beta of 0.80. Armata Pharmaceuticals has a 52-week low of $1.93 and a 52-week high of $4.48.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
See Also
- Five stocks we like better than Armata Pharmaceuticals
- What is the Nasdaq? Complete Overview with History
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- What is a Death Cross in Stocks?
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Consumer Staples Stocks, Explained
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
